Recordati Rare Diseases, Pedea 5 mg/ml solution for injection, EL(22)A/45
PUTEAUX, France--(BUSINESS WIRE)--Recordati Rare Diseases announce today publication of the long-term outcomes from the open-label extension period of the Phase III LINC 3 study of Isturisa® in The European Journal of Endocrinology.1 These data support the long-term utility of Isturisa® in the maintenance treatment of patients with Cushing’s disease and reinforce Isturisa as an effective and well-tolerated oral therapy. Isturisa® is indicated in the EU for the treatment of adult patients with endogenous Cushing’s syndrome,2 a rare and debilitating condition of hypercortisolism that is caused by a pituitary adenoma (Cushing’s disease).3
LEBANON, N.J.--(BUSINESS WIRE)--Recordati Rare Diseases Inc. announced today that the Phase III LINC 3 study demonstrates ISTURISA® (osilodrostat) improves physical features associated with hypercortisolism in patients with Cushing’s disease. ISTURISA is indicated in the United States for the treatment of adult patients with Cushing’s disease. These findings were presented at the American Association of Clinical Endocrinology (AACE) annual meeting by Alberto Pedroncelli MD, Head of Clinical Development & Medical Affairs, Global Endocrinology, Recordati AG.
LEBANON, N.J.--(BUSINESS WIRE)--Recordati Rare Diseases Inc. (RRD), a biopharmaceutical company committed to providing often-overlooked orphan therapies to underserved rare disease communities in the United States and Canada, is pleased to welcome William Ludlam, MD, PhD, in the role of Chief Medical Officer and Vice President - Clinical Development.
PUTEAUX, France--(BUSINESS WIRE)--Recordati Rare Diseases announces that positive results from the Phase III LINC 4 study of Isturisa® were presented on March 22 at The Endocrine Society’s Annual Meeting.1
LEBANON, N.J.--(BUSINESS WIRE)--Recordati Rare Diseases announces that positive results from the Phase III LINC-4 study of Isturisa® have been presented at the Endocrine Society’s annual meeting.
PUTEAUX, France--(BUSINESS WIRE)--Recordati Rare Diseases announces that positive results from the Phase III LINC 4 study of Isturisa® were presented on March 22 at The Endocrine Society’s Annual Meeting.1
LEBANON, N.J., Sept. 15, 2020 /PRNewswire/ -- Recordati Rare Diseases Inc., today announced that CYSTADROPS® (cysteamine ophthalmic solution) 0.37% is now available for prescription and distribution across the United States (U.S.). CYSTADROPS is a new, viscous eye drop solution that depletes cystine crystal deposits in the cornea of the eyes of people living with cystinosis. Cystinosis is a rare genetic condition present from birth that leads to the build-up of cystine crystals throughout the body, causing widespread tissue and organ damage and significant impact on the eyes.
LEBANON, N.J., Aug. 25, 2020 /PRNewswire/ -- Recordati Rare Diseases Inc., today announced the U.S. Food and Drug Administration (FDA) has approved CYSTADROPS® (cysteamine ophthalmic solution) 0.37%. CYSTADROPS is a new, viscous eye drop solution that depletes corneal cystine crystal deposits in people living with cystinosis. CYSTADROPS demonstrated a significant reduction in cystine crystal deposits in the cornea of the eye and is the first and only FDA-approved cysteamine drop formulation with four times a day dosing. Cystinosis is a rare genetic condition present from birth that leads to the build-up of cystine crystals throughout the body, causing widespread tissue and organ damage and significant impact on the eyes.
Recordati's founding family is turning over its 51% controlling stake to CVC Capital in a €3.03 billion cash-and-debt deal.